{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T13:29:14Z","timestamp":1765546154336},"reference-count":42,"publisher":"Impact Journals, LLC","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2017,2,21]]},"DOI":"10.18632\/oncotarget.14393","type":"journal-article","created":{"date-parts":[[2017,1,3]],"date-time":"2017-01-03T12:40:46Z","timestamp":1483447246000},"page":"13085-13098","source":"Crossref","is-referenced-by-count":19,"title":["Emetine elicits apoptosis of intractable B-cell lymphoma cells with <i>MYC<\/i> rearrangement through inhibition of glycolytic metabolism"],"prefix":"10.18632","volume":"8","author":[{"given":"Tomohiro","family":"Aoki","sequence":"first","affiliation":[{"name":"Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuyuki","family":"Shimada","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan"},{"name":"Institute for Advanced Research, Nagoya University, Nagoya, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiko","family":"Sakamoto","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan"},{"name":"Department of Mechanism of Aging, National Center for Geriatrics and Gerontology, Obu, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiki","family":"Sugimoto","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan"},{"name":"Fujii Memorial Research Institute, Otsuka Pharmaceutical Co., Ltd., Otsu, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takanobu","family":"Morishita","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan"},{"name":"Department of Hematology, Japanese Red Cross Nagoya Daiichi Hospital, Nagoya, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Kojima","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoko","family":"Shimada","sequence":"additional","affiliation":[{"name":"Department of Pathology and Clinical Laboratories, Nagoya University Hospital, Nagoya, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seiichi","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Pathology and Clinical Laboratories, Nagoya University Hospital, Nagoya, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chisako","family":"Iriyama","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunsuke","family":"Kuno","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiko","family":"Harada","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Tomita","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan"},{"name":"Department of Hematology, Fujita Health University School of Medicine, Toyoake, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumihiko","family":"Hayakawa","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Kiyoi","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2016,12,31]]},"reference":[{"key":"1","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Vardiman","year":"2008"},{"key":"2","doi-asserted-by":"publisher","first-page":"3884","DOI":"10.1002\/cncr.28899","article-title":"MYC-associated and double-hit lymphomas: a review of pathobiology, prognosis, and therapeutic approaches","volume":"120","author":"Smith","year":"2014","journal-title":"Cancer"},{"key":"3","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1182\/blood-2014-05-578963","article-title":"Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis","volume":"124","author":"Melinamani","year":"2014","journal-title":"Blood"},{"key":"4","doi-asserted-by":"publisher","first-page":"3452","DOI":"10.1200\/JCO.2011.41.0985","article-title":"Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone","volume":"30","author":"Meyer","year":"2012","journal-title":"J Clin Oncol"},{"key":"5","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1038\/leu.2008.344","article-title":"Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t(14;18) and 8q24\/c-MYC translocations","volume":"23","author":"Hirano","year":"2009","journal-title":"Leukemia"},{"key":"6","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.1200\/JCO.2009.26.3947","article-title":"Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab","volume":"28","author":"Jack","year":"2010","journal-title":"J Clin Oncol"},{"key":"7","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1182\/blood-2012-06-435842","article-title":"MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma","volume":"121","author":"Cogliatti","year":"2013","journal-title":"Blood"},{"key":"8","doi-asserted-by":"publisher","first-page":"3533","DOI":"10.1182\/blood-2009-05-220095","article-title":"MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy","volume":"114","author":"Gascoyne","year":"2009","journal-title":"Blood"},{"key":"9","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1182\/blood-2006-08-038257","article-title":"The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP","volume":"109","author":"Connors","year":"2007","journal-title":"Blood"},{"key":"10","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1200\/JCO.2010.33.3419","article-title":"Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP","volume":"29","author":"Gascoyne","year":"2011","journal-title":"J Clin Oncol"},{"key":"11","doi-asserted-by":"publisher","first-page":"4740","DOI":"10.1200\/JCO.2010.29.2813","article-title":"Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium","volume":"28","author":"Pro","year":"2010","journal-title":"J Clin Oncol"},{"key":"12","doi-asserted-by":"publisher","first-page":"11988","DOI":"10.1073\/pnas.1310230110","article-title":"Myc and mTOR converge on a common node in protein synthesis control that confers synthetic lethality in Myc-driven cancers","volume":"110","author":"Ruggero","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"13","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1158\/2159-8290.CD-12-0404","article-title":"The mTORC1 inhibitor everolimus prevents and treats Emu-Myc lymphoma by restoring oncogene-induced senescence","volume":"3","author":"Smyth","year":"2013","journal-title":"Cancer Discov"},{"key":"14","doi-asserted-by":"publisher","first-page":"3406","DOI":"10.1182\/blood-2013-11-538546","article-title":"Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-delta, as therapy for previously treated indolent non-Hodgkin lymphoma","volume":"123","author":"Johnson","year":"2014","journal-title":"Blood"},{"key":"15","doi-asserted-by":"publisher","first-page":"3398","DOI":"10.1182\/blood-2013-11-537555","article-title":"A phase 1 study of the PI3Kdelta inhibitor idelalisib in patients with relapsed\/refractory mantle cell lymphoma (MCL)","volume":"123","author":"Wagner-Johnston","year":"2014","journal-title":"Blood"},{"key":"16","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1111\/bjh.12982","article-title":"Double hit lymphoma: the MD Anderson Cancer Center clinical experience","volume":"166","author":"Nastoupil","year":"2014","journal-title":"Br J Haematol"},{"key":"17","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Jin","year":"2013","journal-title":"Nat Med"},{"key":"18","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1056\/NEJMoa0802885","article-title":"Stromal gene signatures in large-B-cell lymphomas","volume":"359","author":"Fu","year":"2008","journal-title":"N Engl J Med"},{"key":"19","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/nrc2714","article-title":"Environment-mediated drug resistance: a major contributor to minimal residual disease","volume":"9","author":"Dalton","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"20","doi-asserted-by":"publisher","first-page":"3367","DOI":"10.1182\/blood-2009-06-225326","article-title":"The microenvironment in mature B-cell malignancies: a target for new treatment strategies","volume":"114","author":"Caligaris-Cappio","year":"2009","journal-title":"Blood"},{"key":"21","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1182\/blood-2009-10-248054","article-title":"Reconstitution of PTEN activity by CK2 inhibitors and interference with the PI3-K\/Akt cascade counteract the antiapoptotic effect of human stromal cells in chronic lymphocytic leukemia","volume":"116","author":"Schwarzmeier","year":"2010","journal-title":"Blood"},{"key":"22","doi-asserted-by":"publisher","first-page":"3432","DOI":"10.1182\/blood-2014-10-607036","article-title":"Stromal cell-mediated glycolytic switch in CLL cells involves Notch-c-Myc signaling","volume":"125","author":"Mougiakakos","year":"2015","journal-title":"Blood"},{"key":"23","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1126\/science.123.3191.309","article-title":"On the origin of cancer cells","volume":"123","author":"Warburg","year":"1956","journal-title":"Science"},{"key":"24","doi-asserted-by":"publisher","first-page":"13054","DOI":"10.1038\/srep13054","article-title":"Discovery of a drug targeting microenvironmental support for lymphoma cells by screening using patient-derived xenograft cells","volume":"5","author":"Naoe","year":"2015","journal-title":"Sci Rep"},{"key":"25","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1084\/jem.20040254","article-title":"Lymph node fibroblastic reticular cells construct the stromal reticulum via contact with lymphocytes","volume":"200","author":"Shimizu","year":"2004","journal-title":"J Exp Med"},{"key":"26","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.molcel.2010.09.022","article-title":"Hypoxia-inducible factors and the response to hypoxic stress","volume":"40","author":"Simon","year":"2010","journal-title":"Mol Cell"},{"key":"27","doi-asserted-by":"publisher","first-page":"7381","DOI":"10.1128\/MCB.00440-07","article-title":"Hypoxia-inducible factor 1 and dysregulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic switches hexokinase 2 and pyruvate dehydrogenase kinase 1","volume":"27","author":"Dang","year":"2007","journal-title":"Mol Cell Biol"},{"key":"28","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.cmet.2006.01.012","article-title":"HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption","volume":"3","author":"Denko","year":"2006","journal-title":"Cell Metab"},{"key":"29","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/35085588","article-title":"Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas","volume":"412","author":"Dalla-Favera","year":"2001","journal-title":"Nature"},{"key":"30","doi-asserted-by":"publisher","first-page":"23239","DOI":"10.18632\/oncotarget.8096","article-title":"Emetine induces chemosensitivity and reduces clonogenicity of acute myeloid leukemia cells","volume":"7","author":"Risueno","year":"2016","journal-title":"Oncotarget"},{"key":"31","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1021\/np050029m","article-title":"Terpenoid tetrahydroisoquinoline alkaloids emetine, klugine, and isocephaeline inhibit the activation of hypoxia-inducible factor-1 in breast tumor cells","volume":"68","author":"Nagle","year":"2005","journal-title":"J Nat Prod"},{"key":"32","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1158\/0008-5472.CAN-11-3024","article-title":"Modulation of glucose metabolism by CD44 contributes to antioxidant status and drug resistance in cancer cells","volume":"72","author":"Saya","year":"2012","journal-title":"Cancer Res"},{"key":"33","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1002\/1097-0142(197305)31:5<1170::AID-CNCR2820310520>3.0.CO;2-4","article-title":"A phase I study of emetine hydrochloride (NSC 33669) in solid tumors","volume":"31","author":"Weiss","year":"1973","journal-title":"Cancer"},{"key":"34","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.ccr.2007.07.006","article-title":"HIF and c-Myc: sibling rivals for control of cancer cell metabolism and proliferation","volume":"12","author":"Simon","year":"2007","journal-title":"Cancer Cell"},{"key":"35","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.4161\/cc.9.9.11358","article-title":"A therapeutic role for targeting c-Myc\/Hif-1-dependent signaling pathways","volume":"9","author":"Anderson","year":"2010","journal-title":"Cell Cycle"},{"key":"36","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1111\/j.1582-4934.2009.00876.x","article-title":"Development of HIF-1 inhibitors for cancer therapy","volume":"13","author":"Melillo","year":"2009","journal-title":"J Cell Mol Med"},{"key":"37","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.ccr.2004.06.009","article-title":"Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway","volume":"6","author":"Petersen","year":"2004","journal-title":"Cancer Cell"},{"key":"38","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1038\/leu.2016.67","article-title":"Development and analysis of patient derived xenograft mouse models in intravascular large B-cell lymphoma","volume":"30","author":"Naoe","year":"2016","journal-title":"Leukemia"},{"key":"39","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1532\/IJH97.07028","article-title":"Epigenetic regulation of CD20 protein expression in a novel B-cell lymphoma cell line, RRBL1, established from a patient treated repeatedly with rituximab-containing chemotherapy","volume":"86","author":"Naoe","year":"2007","journal-title":"Int J Hematol"},{"key":"40","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.exphem.2012.05.007","article-title":"CML cells expressing the TEL\/MDS1\/EVI1 fusion are resistant to imatinib-induced apoptosis through inhibition of BAD, but are resensitized with ABT-737","volume":"40","author":"Naoe","year":"2012","journal-title":"Exp Hematol"},{"key":"41","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/sj.cdd.4400627","article-title":"Complement mediated cell death is associated with DNA fragmentation","volume":"7","author":"Glennie","year":"2000","journal-title":"Cell Death Differ"},{"key":"42","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s12185-008-0221-1","article-title":"Retention but significant reduction of BCR-ABL transcript in hematopoietic stem cells in chronic myelogenous leukemia after imatinib therapy","volume":"88","author":"Naoe","year":"2008","journal-title":"Int J Hematol"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.14393","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,10]],"date-time":"2020-05-10T16:27:40Z","timestamp":1589128060000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.14393"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,31]]},"references-count":42,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,2,21]]}},"alternative-id":["14393","28055963"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.14393","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,31]]}}}